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Abstract
AIM: To investigate primarily the prognostic value of 
Ki-67, as well as other parameters, in gastrointestinal 
stromal tumors (GISTs).
METHODS: Ki-67, c-KIT, platelet-derived growth factor 
receptor-alpha (PDGFRα), smooth muscle actin (SMA), 
CD34, S100 were stained for immunohistochemis-
try which was performed on formalin-fixed, paraffin-
embeded sections on representative block from each 
case. Proliferation index counted by Ki-67 antibody was 
calculated as a number of positive nuclear reaction 
over 100 cells. Immunoreactivity for c-KIT and PDGFRα 
was evaluated semiquantitatively (weak, intermediate, 
strong) and for c-KIT type of reactivity was analyzed 
(cytoplasmic, membrane and "dot-like" staining). Im-
munoreactivity for SMA, CD34 and S100 were was 
evaluated as positive or negative antigen expression. 
Pathologic parameters investigated in this study includ-
ed tumor size, cell type (pure spindle, pured epitheloid 
mixed spindle and epitheloid), mitotic count, hemor-
rhage, necrosis, mucosal ulceration. Clinical data in-
cluded age, gender, primary tumor location and spread 
of disease. χ 2 test and Student's t -test were used for 
comparisons of baseline characteristics. The Cox’s pro-
portional hazard model was used for univariable and 
multivariable analyses. Survival rates were calculated 
by Kaplan-Meier method and statistical significance 
was determined by the log-rank test.
RESULTS: According to the stage of disease, there 
were 36 patients with localized disease, 29 patients 
with initially localized disease but with its recurrence 
in the period of follow up, and finally, 35 patients had 
metastatic disease from the very beginning of disease. 
Tumor originated most commonly in the stomach (41%), 
small intestine was the second most common location 
(36%). The mean size of primary tumors was 6.5 cm. 
The mean duration of follow-up was 60 mo. Multiple 
parameters were analyzed for their effect on overall 
survival, but no one reached statistical significance 
(P  = 0.06). Analysis of time to progression/relapse in 
initially localized disease (univariate analysis), tumor 
size, mitotic count, Ki-67 and type of d-KIT distribution 
(cytoplasmic vs  membrane/”dot-like”) showed statisti-
cally significant correlation. In multivariate analysis in 
the group of patients with localized disease, there were 
only 2 parameters that have impact on relapse, Ki-67 
and SMA (P  < 0.0001 and P  < 0.034, respectively). 
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Furthermore, Ki-67 was analyzed in localized disease vs  
localized with recurrence and metastatic disease. It was 
shown that there is a strict difference between these 2 
groups of patients (median value was 2.5 for localized 
disease vs  10.0 for recurrent/metastatic disease, P  < 
0.0001). It was also shown that the cut-off value which 
is still statistically significant in terms of relapse on the 
level of 6%. The curves for survival on that cut-off level 
are significantly different (P  < 0.04, Cox F).
CONCLUSION: Ki-67 presents a significant prognostic 
factor for GIST recurrence which could be of great im-
portance in evaluating malignant potential of disease.
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Gastrointestinal stromal tumors (GIST) present a wide 
spectrum of  tumors with variable malignant potential[1-3]. 
Although this entity has been defined rather recently, ret-
rospectively it has been shown to be the most frequent 
mesenchymal neoplasm arising in the gastrointestinal 
tract[4]. Namely, in the last few decades, GISTs were so­
metimes wrongly diagnosed as leiomyoma, leiomyosar-
coma and schwannoma. However, immunohistochemial 
staining and electron microscopic studies suggested dif-
ference comparing to other smooth muscle or Schwann 
cells. Finally, Hirota et al[5] demonstrated in 1998. muta-
tion of  c-KIT proto-oncogen as a paradigm of  single-
mutation tumorogenesis. It has also been shown that 
GIST originates from interstitial cells of  Cajal[6]. 
Today we also know that both c-KIT and platelet-
derived growth factor receptor-alpha (PDGFRα) oncop-
roteins are growth factor receptors that are normally acti-
vated by specific ligand stem cell factor. Their mutations 
lead to an independent activation of  the receptor and 
constitutive activation and proliferation of  cells[5]. Along 
with KIT­expression, very often is expressed CD34 and 
sometimes smooth muscle actin (SMA; focal of  diffuse)[7].
The prediction of  GIST behavior still remains con-
troversial after all these years and, in many cases, non-
conclusive. Many prognostic factors have been suggested 
and investigated in previous studies[8]. It is well known 
and established that the size of  tumor (> 5 cm), mitotic 
rate > 5/50 HPF and site of  the tumor play an impor-
tant role. Nevertheless, it is not quite possible to predict 
the behavior of  all GISTs. According to guidelines for 
the assessment of  likely behavior, GISTs have been tra-
ditionally divided into probably benign, malignant and 
uncertain/low malignant potential (Fletcher)[9].
Imatinib mesylate, a selective tyrosine kinase inhibi-
tor, has been known to have activity against such tumors. 
However, no patient had a complete response to the 
treatment so delineating prognostic factors for patients 
with GIST may be important even in post imatinib era[10]. 
It is not clear as well whether there is a role of  adjuvant 
treatment in some GIST patients, although some current 
trials are still on going[11].
Ki-67 is a nuclear proliferation associated antigen. It 
is expressed in the growth and synthesis phases of  the 
cell cycle but not in G0-phase (resting phase)[12]. It is a 
rather reliable marker of  cell proliferation although there 
are differences between studies of  Ki­67 labeling index, 
ranging from 4% to 22%[13,14]. 
The aim of  this study was to investigate the role of  
Ki­67 among other parameters, as a prognostic factor of  
clinical behavior and prognosis, along with morphological 
and immunohistochemical profile in 100 GIST patients.
MATERIALS AND METHODS
All mesenchymal tumors of  the gastrointestinal tract 
were retrieved from the files of  the University Hospital 
Center Zagreb, in the period from 1997­2007. Since the 
immunohistochemistry has been developed on routine 
basis from the 2001, all specimens obtained before that 
time were retrospectively analyzed for c-KIT positivity. 
Inclusion criteria for the study were appropriate mor-
phology and c-KIT positivity. Clinical data were retrieved 
from the files of  the Clinic of  Oncology and Surgical 
Oncology. Follow-up information was obtained from 
patients records or interviews. Clinical data included age, 
gender, tumor location (esophagus, stomach, small intes-
tine, large bowel, retroperitoneum, mesentery) and spread 
of  the disease. Spread of  disease was classified into three 
groups: localized disease, localized disease with recur-
rence and metastatic disease. Pathological parameters that 
were assesed included tumor size, mitotic count, cell type 
(pure spindle, mixed spindle and epithelioid, pure epithe-
loid), necrosis, hemorrhagic areas and mucosal ulceration 
(invasion of  lamina propria). Tumor size was measured 
in three dimensions and the largest dimension was taken 
into account. The mitoses were counted on 50 HPFx (400 
×). Immunohistochemistry was performed on formalin-
fixed, paraffin­embedded sections on representative block 
from each case. Following antibodies were used: CD-117 
(Dako, Glostrup, Denmark), CD34 (DAKO), PDGFRα 
(Novocastra, England), SMA (SMA­1, DAKO), S­100 
(DAKO), Ki­67 (MIB­5, DAKO). Positive controls were 
included. All samples were evaluated by two experienced 
pathologists. Immunoreactivity for c-KIT and PDGFRα 
was evaluated semiquantitatively (weak, intermediate and 
strong), and c­KIT type of  reactivity was analyzed (cy-
toplasmic, membrane or “dot­like” staining). Proliferat-
ing index counted by Ki-67 antibody was calculated as a 
number of  positive nuclear reaction over 100 cells. Im-
munoreactivity for SMA, S100 and CD34 was evaluated 
as positive or negative antigen expression.
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Statistical analysis
χ 2 test or Student’s t-test was used for statistical compari-
sons of  baseline characteristics. In statistical analysis of  
our results we also used appropriate descriptive methods 
(median, range, minimum and maximum). The Cox’s 
proportional hazard model was used in univariable and 
multivariable analyses. Survival rates were calculated by 
the Kaplan­Meier method, and statistical significance 
was determined by the log-rank test. The observed dif-
ferences were assumed to be statistically significant if  the 
probability of  chance occurence was P < 0.05. All sta-
tistical analysis were performed by the statistical package 
statistica.
RESULTS
Our study comprised 100 GIST patients. Mean patients’ 
age was 60.5 (range 20-78) years; 56% of  patients were 
men. Patient distribution in three groups according to 
sex and age is shown in Table 1. There were 36 patients 
presenting initially with localized disease, 29 had local-
ized disease further with recurrence and 35 had meta-
static disease from the very beginning. Tumors origi-
nated most commonly in the stomach (41%), the small 
intestine was the second most common location (36%), 
in 8% colon and rectum and in 5% retroperitoneum was 
involved. In 10% of  cases primary site of  GIST was not 
clearly determined, because of  the wide spread of  the 
disease. The mean size of  primary tumors (in patients 
without metastases) was 6.5 cm and 35 patients had dis-
tant metastases in the time of  diagnosis. Metastases were 
most often localized in the liver, all other sites were rarely 
involved. The mean duration of  follow-up was 60 (range 
28-110) mo. Survival curve for all patients included in 
our study is shown in Figure 1. Further on, multiple 
parameters were analyzed for their effect on overall sur-
vival in all patients (Table 2). Most of  them showed no 
effect, more precisely, only 2 parameters are close to sta-
tistically significant prediction of  outcome and biological 
behavior, on the level of  P = 0.06. These are Ki-67 and 
type of  distribution of  c­KIT. On the contrary, when we 
analyzed time to progression/relapse in localized disease, 
in univariate analysis tumor size, mitotic rate, Ki­67 and 
type of  c-KIT distribution (cytoplasmic vs membrane/
“dot­like“) showed statistically significant correlation. 
In multivariate analysis in the group of  patients with 
localized disease, there were only 2 parameters that have 
impact on relapse, Ki­67 and SMA expression (Table 3). 
Furthermore, when we compared Ki­67 in three differ-
ent patients group it was obvious that there is a strict dif-
ference between mean value of  Ki-67 in localized disease 
vs recurrent and metastatic disease together (median in 
localized disease was 2.5 vs 10.0 in recurrent and meta-
static disease, P < 0.0001). It was shown that the cut-
off  value which is still statistically significant in terms of  
relapse on the level of  6% (Figure 2). Also, it has been 
shown that the curves for survival on that cut-off  level 
are significantly different (P = 0.04, Cox F-test; Figure 3).
DISCUSSION
According to data obtained from our study, like age, sex 
distribution and primary localization, they are compa-
rable to previous data in literature[8,15,16]. GISTs are rather 
rare tumors with very interesting biological behavior and 
sometimes unpredictable clinical course[17-19]. Although 
many reports indicated that the size and mitotic count 
are the most important and reliable prognostic factors[7], 
it has become obvious that the primary tumor localiza-
tion was also very important issue[17]. Some 10 years ago, 
DeMatteo et al[20] showed that only tumor size is reliable 
predictor of  survival in multivariate analysis. Some other 
Table 1  Patient distribution according to sex and age in three 
different groups
Groups Sex Total
Male Female
Localized disease Number 19 17 36
Average age (yr)    59.5    62.9    61.1
Recurrent disease Number 17 12 29
Average age (yr)    55.5    58.4    56.7
Metastatic disease Number 20 15 35
Average    60.7    48.7    55.5
Total Number 56 44       100
Average age (yr)    58.7    56.8    57.9
Table 2  Multivariate analysis of different parameters for sur-
vival in all analyzed patients (n  =100)
Parameter Beta Standard 
error
t  
value
P  
value
Tumor size  0.04 0.03  1.12 0.26
Mitosis -0.01 0.01 -0.91 0.35
Necrosis  0.76 0.73  1.04 0.29
Haemorrhage -0.63 0.68 -0.93 0.35
Ki-67  0.05 0.02  1.83 0.06
c-KIT  1.44 0.79  1.83 0.06
SMA  0.19 0.51  0.38 0.70
S100 -0.33 0.67 -0.49 0.62
CD34 -0.34 0.52 -0.66 0.50
Cell morphology -0.19 0.52 -0.37 0.70
SMA: Smooth muscle actin.Table 3  Multivariate analysis of different parameters for the 
disease free interval in patients with initially localized disease 
(n  = 65)
Parameter Beta Standard 
error
t  
value
Exponent 
beta
P  
value
Tumor size   0.052 0.031   1.643 1.053 0.100
Number of mitosis   0.011 0.014   0.797 1.011 0.424
Necrosis   0.525 0.633   0.830 1.691 0.406
Haemorrhage   0.865 0.673   1.285 2.377 0.198
Ki-67   0.113 0.030   3.778 1.120 0.0001
c-KIT   0.592 0.536   1.102 1.807 0.270
SMA -1.213 0.575 -2.110 0.297 0.034
S100 -0.237 0.771 -0.308 0.788 0.757
CD34 -1.088 0.562 -1.935 0.336 0.052
SMA: Smooth muscle actin.
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authors found tumor size > 5 cm a poor prognostic fac-
tors[21]. However, there are only few reports of  Ki­67 as 
a good indicator of  the risk of  metastases and as a prog-
nostic factor[22]. Among other parameters, it was used for 
distinguishing leiomyoma and leiomyosarcoma[23]. Car-
rillo et al[13] stated that Ki-67 is one of  the most accurate 
predictor of  clinical behavior in GIST although it was 
not confirmed always and some other authors reported 
about Ki-67 with mitotic index as a prognostic factors 
in stomach GISTs[24]. In addition, we showed in our 
study, that there is no statistically significant difference in 
mean Ki-67 value between stomach- and small intestine-
localization of  GIST (52 patients together, 29 vs 23) (data 
not shown). That might support an idea of  Ki-67 as a 
non­location­specific prognostic factor, what could be 
its advantage comparing to mitotic indeks which shows 
strong correlation to anatomic site of  tumor.
One of  the most important fact is observation that 
the level of  Ki-67 is a prognostic factor for the relapse 
of  initially localized disease (P < 0.0001), and the cut­off  
value is on 6%. Even in the survival setting this distinc-
tion remains statistically significant, no matter how these 
patients were treated (P = 0.04, Cox F-test). The expres-
sion of  Ki­67 changes widely from one to another study, 
probably by the variety of  cut-offs of  various authors. 
Toquet et al[25] and Nakamura et al[26] described cut-off  of  
10%, some others on the level of  5%. In that sense, our 
finding is important as additional indicator of  importance 
of  Ki­67 no matter the origin of  GIST, and as well this 
might suggest, among other factors, which patient might 
have a greater risk of  disease relaps. Maybe it might in-
dicate the patients suitable for adjuvant treatment after 
surgical resection of  localized GIST, in addition to con-
temporary concept of  high-risk disease.
Considering other analyzed parameters, no one show­
ed statistical power and impact on survival, as we ex-
pected. Just to mention that the meaning of  statistical 
significance of  SMA in DFI (P < 0.034) should be cau-
tiously interpreted. It might be based on the fact that we 
assumed SMA-positive tumors generally better differen-
tiated ones, thus it is to expect less aggressive course of  
disease which means fewer recurrences.
In conclusion, although there are some differences in 
numerical values of  Ki­67 in various studies , that may be 
caused by different methodology in the assessment. But 
Ki-67 stays very important parameter of  GIST-prognosis 
and should not be neglected when assessing malignant 
potential of  the GIST.
COMMENTS
Background
Gastrointestinal stromal tumors (GIST) have a specific tumor biology with a 
wide spectrum of clinical behaviors. Thus, it is of great importance to define 
prognostic factors which could indicate risk of recurrence or spread of disease. 
Ki-67 is potentially good prognostic factor.
Research frontiers
So far, some of prognostic factors were rather well documented as the prognos-
tic factors of further tumor behavior, for example mitotic count and tumor size, 
along with tumor primary localization. Ki-67 was unequivocally addressed as a 
prognostic factor. 
Innovations and breakthroughs
This is the first study showing so clearly the significance of Ki-67 as a prognos-
tic factor. Of importance is, that the patients included in the study were in differ-
ent stage of disease, and also that comparison to other parameters have been 
done. It was shown that the cut-off value of Ki-67 of 6%, present the borderline 
value for recurrence of initially localized disease. 
Applications
By understanding the meaning of Ki-67, it could be used as a parameter pre-
dicting tumor recurrence and suggest adjuvant treatment after surgery of local-
ized disease.
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Figure 3  Survival curves with different values of Ki-67 (cut-off on 6%).
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Terminology
Ki-67 or MKI-67 is a protein that is in humans encoded by MKI-67 gene. Ki-67 
antigen is associated, and probably necessary, for cellular proliferation, it is 
associated with ribosomal RNA transcription. It is to assume that higher Ki-67 
reveals tumor cell activity and thus predicts further behavior.
Peer review
This study is a contribution to the knowledge of GIST. It has a great value in 
better understanding of the biology of the disease, since some other param-
eters have already been recognized important as prognostic factors.
REFERENCES
1 Goss GA, Merriam P, Manola J Singer S, Fletcher C, Demetri 
G. Clinical and pathological characteristics of gastrointesti-
nal stromal tumors (GIST). Prog Proc Am Soc Clin Oncol 2000; 
19: 2000
2 Franquemont DW. Differentiation and risk assessment of 
gastrointestinal stromal tumors. Am J Clin Pathol 1995; 103: 
41-47 [PMID: 7817943]
3 Clary BM, DeMatteo RP, Lewis JJ, Leung D, Brennan MF. 
Gastrointestinal stromal tumors and leiomyosarcoma of the 
abdomen and retroperitoneum: a clinical comparison. Ann 
Surg Oncol 2001; 8: 290-299 [PMID: 11352301 DOI: 10.1245/
aso.2001.8.4.290]
4 Nishida T, Hirota S. Biological and clinical review of stromal 
tumors in the gastrointestinal tract. Histol Histopathol 2000; 
15: 1293-1301 [PMID: 11005253]
5 Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, 
Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Mu-
hammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura 
Y, Kitamura Y. Gain-of-function mutations of c-kit in human 
gastrointestinal stromal tumors. Science 1998; 279: 577-580 
[PMID: 9438854 DOI: 10.1126/science.279.5350.577]
6 Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom 
JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastro-
intestinal stromal tumors show phenotypic characteristics of 
the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269 
[PMID: 9588894]
7 Saul SH, Rast ML, Brooks JJ. The immunohistochemistry of 
gastrointestinal stromal tumors. Evidence supporting an ori-
gin from smooth muscle. Am J Surg Pathol 1987; 11: 464-473 
[PMID: 3035954 DOI: 10.1097/00000478-198706000-00007]
8 Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dor-
tok A, Gustavsson B, Sablinska K, Kindblom LG. Gastroin-
testinal stromal tumors: the incidence, prevalence, clinical 
course, and prognostication in the preimatinib mesylate era-
-a population-based study in western Sweden. Cancer 2005; 
103: 821-829 [PMID: 15648083 DOI: 10.1002/cncr.20862]
9 Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, 
Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, 
Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointesti-
nal stromal tumors: A consensus approach. Hum Pathol 2002; 
33: 459-465 [PMID: 12094370 DOI: 10.1053/hupa.2002.123545]
10 Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, 
Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimi-
trijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase 
inhibitor STI571 in a patient with a metastatic gastrointesti-
nal stromal tumor. N Engl J Med 2001; 344: 1052-1056 [PMID: 
11287975 DOI: 10.1056/NEJM200104053441404]
11 Nilsson B, Sjölund K, Kindblom LG, Meis-Kindblom JM, Bü-
mming P, Nilsson O, Andersson J, Ahlman H. Adjuvant ima-
tinib treatment improves recurrence-free survival in patients 
with high-risk gastrointestinal stromal tumours (GIST). Br J 
Cancer 2007; 96: 1656-1658 [PMID: 17533389 DOI: 10.1038/ 
sj.bjc.6603797]
12 Seidal T, Edvardsson H. Expression of c-kit (CD117) and 
Ki67 provides information about the possible cell of origin 
and clinical course of gastrointestinal stromal tumours. His-
topathology 1999; 34: 416-424 [PMID: 10231416 DOI: 10.1046/
j.1365-2559.1999.00643.x]
13 Carrillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognos-
tic significance of DNA ploidy and proliferative index (MIB-1 
index) in gastrointestinal stromal tumors. Hum Pathol 1997; 
28: 160-165 [PMID: 9023396 DOI: 10.1016/S0046-8177(97) 
90100-3]
14 Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt 
D. Immunophenotype, proliferation, DNA ploidy, and bio-
logical behavior of gastrointestinal stromal tumors: a multi-
variate clinicopathologic study. Hum Pathol 1998; 29: 791-800 
[PMID: 9712419 DOI: 10.1016/S0046-8177(98)90447-6]
15 Saund MS, Demetri GD, Ashley SW. Gastrointestinal stro-
mal tumors (GISTs). Curr Opin Gastroenterol 2004; 20: 89-94 
[PMID: 15703627 DOI: 10.1097/00001574-200403000-00007]
16 Kindblom LG, Meis-Kindblom J, Bumming P, Dimitrijevic 
S, Miret M, Dortok A. Incidence, prevalence, phenotype and 
biologic spectrum of gastrointestinal stromal tumors (GIST) 
- A population-based study of 600 cases. Ann Oncol 2003: 13 
(Suppl 5): 157
17 Strickland L, Letson GD, Muro-Cacho CA. Gastrointesti-
nal stromal tumors. Cancer Control 2008; 8: 252-261 [PMID: 
11378651]
18 Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal 
tumor. Surg Oncol 2008; 17: 129-138 [PMID: 18234489 DOI: 
10.1016/j.suronc.2007.12.002]
19 Miettinen M, Lasota J. Gastrointestinal stromal tumors--def-
inition, clinical, histological, immunohistochemical, and mo-
lecular genetic features and differential diagnosis. Virchows 
Arch 2001; 438: 1-12 [PMID: 11213830 DOI: 10.1007/s0042 
80000338]
20 Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki 
RG, Singer S, Besmer P, Brennan MF, Antonescu CR. Tumor 
mitotic rate, size, and location independently predict recur-
rence after resection of primary gastrointestinal stromal tu-
mor (GIST). Cancer 2008; 112: 608-615 [PMID: 18076015 DOI: 
10.1002/cncr.23199]
21 Kwon SJ. Surgery and prognostic factors for gastric stromal 
tumor. World J Surg 2001; 25: 290-295 [PMID: 11343178 DOI: 
10.1007/s002680020040]
22 Ohdaira H, Ohyama S, Yamaguchi T, Yanagisawa A, Kato 
Y, Urashima M. Ki67 and tumor size as prognostic factors of 
gastrointestinal stromal tumors. JMAJ 2005; 48: 586-592
23 Matsuda K, Watanabe H, Nishikura K, Endoh Y, Ajioka Y, 
Hitomi J. Gastric myogenic tumors Its Ki-67 mitotic count, 
myogenic markers, histogenesis of sarcoma and differentia-
tion from gastric stromal tumor. Stomach and Intestine (Tokyo) 
1995; 30: 1109-1124
24 Nagasako Y, Misawa K, Kohashi S, Hasegawa K, Okawa Y, 
Sano H, Takada A, Sato H. Evaluation of malignancy using 
Ki-67 labeling index for gastric stromal tumor. Gastric Can-
cer 2003; 6: 168-172 [PMID: 14520530 DOI: 10.1007/s10120- 
003-0246-3]
25 Toquet C, Le Néel JC, Guillou L, Renaudin K, Hamy A, Hey-
mann MF, Simon-Valla S, Le Borgne J, Maugard C, Fiche M. 
Elevated (& gt; or = 10%) MIB-1 proliferative index correlates 
with poor outcome in gastric stromal tumor patients: a study 
of 35 cases. Dig Dis Sci 2002; 47: 2247-2253 [PMID: 12395897]
26 Nakamura N, Yamamoto H, Yao T, Oda Y, Nishiyama K, 
Imamura M, Yamada T, Nawata H, Tsuneyoshi M. Prognos-
tic significance of expressions of cell-cycle regulatory proteins 
in gastrointestinal stromal tumor and the relevance of the risk 
grade. Hum Pathol 2005; 36: 828-837 [PMID: 16084954]
P- Reviewers  Chen P, Linhares E    S- Editor  Wen LL
L- Editor  A    E- Editor  Xiong L
Belev B et al . Role of Ki-67 in GIST
